This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Triant, V. A. Articles by Grinspoon, S. K. Search for Related Content PubMed PubMed Citation Articles by Triant, V. A. Articles by Grinspoon, S. K. Related Collections Lipid Cardiovascular Endocrinology Diabetes and Insulin

Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease

Massachusetts General Hospital Program in Nutritional Metabolism (V.A.T., C.H., S.K.G.), Brigham and Women’s Hospital and Massachusetts General Hospital Divisions of Infectious Diseases (V.A.T.), and the Massachusetts General Hospital Biostatistics Center (H.L.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Steven K. Grinspoon, M.D., Program in Nutritional Metabolism, Massachusetts General Hospital, 55 Fruit Street, Longfellow 207, Boston, Massachusetts 02114. E-mail: sgrinspoon{at}partners.org.

Context: Metabolic changes and smoking are common among HIV patients and may confer increased cardiovascular risk.

Objective: The aim of the study was to determine acute myocardial infarction (AMI) rates and cardiovascular risk factors in HIV compared with non-HIV patients in two tertiary care hospitals.

Design, Setting, and Participants: We conducted a health care system-based cohort study using a large data registry with 3,851 HIV and 1,044,589 non-HIV patients. AMI rates were determined among patients receiving longitudinal care between October 1, 1996, and June 30, 2004.

Main Outcome Measures: The primary outcome was myocardial infarction, identified by International Classification of Diseases coding criteria.

Results: AMI was identified in 189 HIV and 26,142 non-HIV patients. AMI rates per 1000 person-years were increased in HIV vs. non-HIV patients [11.13 (95% confidence interval [CI] 9.58–12.68) vs. 6.98 (95% CI 6.89–7.06)]. The HIV cohort had significantly higher proportions of hypertension (21.2 vs. 15.9%), diabetes (11.5 vs. 6.6%), and dyslipidemia (23.3 vs. 17.6%) than the non-HIV cohort (P < 0.0001 for each comparison). The difference in AMI rates between HIV and non-HIV patients was significant, with a relative risk (RR) of 1.75 (95% CI 1.51–2.02; P < 0.0001), adjusting for age, gender, race, hypertension, diabetes, and dyslipidemia. In gender-stratified models, the unadjusted AMI rates per 1000 person-years were higher for HIV patients among women (12.71 vs. 4.88 for HIV compared with non-HIV women), but not among men (10.48 vs. 11.44 for HIV compared with non-HIV men). The RRs (for HIV vs. non-HIV) were 2.98 (95% CI 2.33–3.75; P < 0.0001) for women and 1.40 (95% CI 1.16–1.67; P = 0.0003) for men, adjusting for age, gender, race, hypertension, diabetes, and dyslipidemia. A limitation of this database is that it contains incomplete data on smoking. Smoking could not be included in the overall regression model, and some of the increased risk may be accounted for by differences in smoking rates.

Conclusions: AMI rates and cardiovascular risk factors were increased in HIV compared with non-HIV patients, particularly among women. Cardiac risk modification strategies are important for the long-term care of HIV patients.

This article has been cited by other articles:

				M. D Fan, B.-S. Maslow, N. Santoro, and E. Schoenbaum HIV and the menopause Menopause Int, December 1, 2008; 14(4): 163 - 168. [Abstract] [Full Text] [PDF]

				F. J. Torriani, L. Komarow, R. A. Parker, B. R. Cotter, J. S. Currier, M. P. Dube, C. J. Fichtenbaum, M. Gerschenson, C. K.C. Mitchell, R. L. Murphy, et al. Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s J. Am. Coll. Cardiol., August 12, 2008; 52(7): 569 - 576. [Abstract] [Full Text] [PDF]

				T. S Sharma, D. D Kinnamon, C. Duggan, G. A Weinberg, L. Furuta, L. Bechard, J. Nicchitta, S. L Gorbach, and T. L Miller Changes in macronutrient intake among HIV-infected children between 1995 and 2004 Am. J. Clinical Nutrition, August 1, 2008; 88(2): 384 - 391. [Abstract] [Full Text] [PDF]

				T. T. Brown Approach to the Human Immunodeficiency Virus-Infected Patient with Lipodystrophy J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2937 - 2945. [Abstract] [Full Text] [PDF]

				S. K. Grinspoon, C. Grunfeld, D. P. Kotler, J. S. Currier, J. D. Lundgren, M. P. Dube, S. E. Lipshultz, P. Y. Hsue, K. Squires, M. Schambelan, et al. State of the Science Conference: Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS: Executive Summary Circulation, July 8, 2008; 118(2): 198 - 210. [Full Text] [PDF]

				J. S. Currier, J. D. Lundgren, A. Carr, D. Klein, C. A. Sabin, P. E. Sax, J. T. Schouten, M. Smieja, and for Working Group 2 Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy Circulation, July 8, 2008; 118(2): e29 - e35. [Full Text] [PDF]

				M. Schambelan, P. W.F. Wilson, K. E. Yarasheski, W. T. Cade, V. G. Davila-Roman, R. B. D'Agostino Sr, T. A. Helmy, M. Law, K. E. Mondy, S. Nachman, et al. Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients Circulation, July 8, 2008; 118(2): e48 - e53. [Full Text] [PDF]

				J. H. Stein, C. M. Hadigan, T. T. Brown, E. Chadwick, J. Feinberg, N. Friis-Moller, A. Ganesan, M. J. Glesby, D. Hardy, R. C. Kaplan, et al. Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients Circulation, July 8, 2008; 118(2): e54 - e60. [Full Text] [PDF]

				K. Samaras Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection J. Antimicrob. Chemother., February 1, 2008; 61(2): 238 - 245. [Abstract] [Full Text] [PDF]

				J. Falutz, S. Allas, K. Blot, D. Potvin, D. Kotler, M. Somero, D. Berger, S. Brown, G. Richmond, J. Fessel, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV N. Engl. J. Med., December 6, 2007; 357(23): 2359 - 2370. [Abstract] [Full Text] [PDF]